ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST

IRVINE, Calif., Jan. 17, 2014 /PRNewswire/ -- ChromaDex Corp.^® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.

Jaksch will also be available during the conference for one-on-one meetings. To schedule a meeting, please contact your Noble Financial representative or contact Bob Prag at The Del Mar Consulting Group, Inc. at (858) 361-1786 or [email protected].

At the time of the presentation, a live audio and high-definition video webcast of the ChromaDex presentation and a copy of the presentation materials will be available through the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/TEN/2014.htm or at http://noble.mediasite.com/mediasite/Play/2ea55381d9a443f8809a80b7677255801d 

Those wishing to listen are encouraged to register at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download is available from the presentation link) to participate. The webcast and presentation will also be archived on www.chromadex.com for 90 days following the event.

About Noble Financial:

Noble Financial Capital Markets was established in 1984; 2014 marks its 30th Anniversary. Noble Financial is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120 - 150  presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com

About ChromaDex^®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin; PURENERGY™, a caffeine-pTeroPure co-crystal; pTeroPure® pterostilbene; and, ProC3G™, a natural black rice containing cyanidin-3-glucoside.  To learn more about ChromaDex, visit www.chromadex.com. 

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Contact:  

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
[email protected] 

or

Alex Partners, LLC
Scott Wilfong, President
425- 242-0891
[email protected] 

ChromaDex Company Contact:

Laura Carney, Executive Assistant
949-419-0288
[email protected] 

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex / Beckerman PR